报价延迟最少15分钟:2026/02/28 00:50 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.38 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.14/-1.24
|
|
企业价值
582.36M
|
| 资产负债 |
|
每股账面净值
3.01
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
80.00M
|
|
每股收益
0.04
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF inductionand improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases. |
